These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 21481946)
1. Are CYP1A2*1F and *1C associated with clozapine tolerability?: a preliminary investigation. Bolla E; Bortolaso P; Ferrari M; Poloni N; Callegari C; Marino F; Lecchini S; Vender S; Cosentino M Psychiatry Res; 2011 Oct; 189(3):483. PubMed ID: 21481946 [No Abstract] [Full Text] [Related]
2. Association between CYP1A2 polymorphisms and clozapine-induced adverse reactions in patients with schizophrenia. Ferrari M; Bolla E; Bortolaso P; Callegari C; Poloni N; Lecchini S; Vender S; Marino F; Cosentino M Psychiatry Res; 2012 Dec; 200(2-3):1014-7. PubMed ID: 22901441 [TBL] [Abstract][Full Text] [Related]
3. Development of asymptomatic pancreatitis with paradoxically high serum clozapine levels in a patient with schizophrenia and the CYP1A2*1F/1F genotype. Sani G; Kotzalidis GD; Simonetti A; Solfanelli A; Mancinelli I; Calabrò G; De Rossi P; De Luca O; Gentile G; Lionetto L; Manfredi G; Girardi N; Ambrosi E; Simmaco M; Tatarelli R J Clin Psychopharmacol; 2010 Dec; 30(6):737-9. PubMed ID: 21057239 [No Abstract] [Full Text] [Related]
4. Respiratory infections rather than antibiotics may increase clozapine levels: a critical review of the literature. de Leon J J Clin Psychiatry; 2004 Aug; 65(8):1144-5. PubMed ID: 15323602 [No Abstract] [Full Text] [Related]
5. Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients. Ammar H; Chadli Z; Mhalla A; Khouadja S; Hannachi I; Alshaikheid M; Slama A; Ben Fredj N; Ben Fadhel N; Ben Romdhane H; Chaabane A; Boughattas NA; Gaha L; Zarrouk L; Aouam K Pharmacogenomics J; 2021 Oct; 21(5):551-558. PubMed ID: 33731885 [TBL] [Abstract][Full Text] [Related]
6. Development of a high throughput single nucleotide polymorphism screening method for the cytochrome P450 1A2 polymorphisms CYP1A2*1C and CYP1A2*1F: are they useful as predictive markers in mental disorders? Klemm M; Eidens M; Lorenz M; Prause S; Weise A; Dahmen N; Forst T; Pfützner A Clin Lab; 2010; 56(9-10):473-80. PubMed ID: 21086794 [TBL] [Abstract][Full Text] [Related]
7. The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients. Kootstra-Ros JE; Smallegoor W; van der Weide J Ann Clin Biochem; 2005 May; 42(Pt 3):216-9. PubMed ID: 15949157 [TBL] [Abstract][Full Text] [Related]
8. Clozapine, mental retardation, and severe psychiatric illness: clinical response in the first year. Rubin M; Langa A Harv Rev Psychiatry; 1995; 2(5):293-4. PubMed ID: 9384915 [No Abstract] [Full Text] [Related]
9. Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. Ozdemir V; Kalow W; Okey AB; Lam MS; Albers LJ; Reist C; Fourie J; Posner P; Collins EJ; Roy R J Clin Psychopharmacol; 2001 Dec; 21(6):603-7. PubMed ID: 11763009 [TBL] [Abstract][Full Text] [Related]
10. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. Eap CB; Bender S; Jaquenoud Sirot E; Cucchia G; Jonzier-Perey M; Baumann P; Allorge D; Broly F J Clin Psychopharmacol; 2004 Apr; 24(2):214-9. PubMed ID: 15206669 [TBL] [Abstract][Full Text] [Related]
11. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Bondolfi G; Morel F; Crettol S; Rachid F; Baumann P; Eap CB Ther Drug Monit; 2005 Aug; 27(4):539-43. PubMed ID: 16044115 [TBL] [Abstract][Full Text] [Related]
12. The CYP1A2 -163C>A polymorphism is associated with clozapine-induced generalized tonic-clonic seizures in Brazilian schizophrenia patients. Kohlrausch FB; Severino-Gama C; Lobato MI; Belmonte-de-Abreu P; Carracedo A; Hutz MH Psychiatry Res; 2013 Sep; 209(2):242-5. PubMed ID: 23601795 [TBL] [Abstract][Full Text] [Related]
13. Omeprazole reduces clozapine plasma concentrations. A case report. Frick A; Kopitz J; Bergemann N Pharmacopsychiatry; 2003 May; 36(3):121-3. PubMed ID: 12806570 [TBL] [Abstract][Full Text] [Related]
14. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Tiwari AK; Deshpande SN; Rao AR; Bhatia T; Mukit SR; Shriharsh V; Lerer B; Nimagaonkar VL; Thelma BK Pharmacogenomics J; 2005; 5(1):60-9. PubMed ID: 15505641 [TBL] [Abstract][Full Text] [Related]
15. Utilizing plasma drug levels and genetic testing to achieve optimal treatment response in a patient with treatment-resistant schizoaffective disorder. Xu JJ; Xiao C; Pan Y; Tang YL; Wang M; Li S; Xie G; Du J; Ren Y; Wang W Bipolar Disord; 2024 Feb; 26(1):95-97. PubMed ID: 38097824 [TBL] [Abstract][Full Text] [Related]
16. The use of clozapine among individuals with intellectual disability: a review. Singh AN; Matson JL; Hill BD; Pella RD; Cooper CL; Adkins AD Res Dev Disabil; 2010; 31(6):1135-41. PubMed ID: 20692809 [TBL] [Abstract][Full Text] [Related]
17. CYP1A2 polymorphism -1545C > T (rs2470890) is associated with increased side effects to clozapine. Viikki M; Kampman O; Seppälä N; Mononen N; Lehtimäki T; Leinonen E BMC Psychiatry; 2014 Feb; 14():50. PubMed ID: 24555493 [TBL] [Abstract][Full Text] [Related]
18. Clozapine: exploring clients' experiences of treatment. McAllister M; Chatterton R Aust N Z J Ment Health Nurs; 1996 Sep; 5(3):136-42. PubMed ID: 9079309 [TBL] [Abstract][Full Text] [Related]
19. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. Basile VS; Masellis M; McIntyre RS; Meltzer HY; Lieberman JA; Kennedy JL J Clin Psychiatry; 2001; 62 Suppl 23():45-66. PubMed ID: 11603885 [TBL] [Abstract][Full Text] [Related]
20. Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia. Tay JK; Tan CH; Chong SA; Tan EC Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1297-302. PubMed ID: 17611010 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]